Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O75369: Variant p.Phe161Cys

Gene: FLNB
Variant information Variant position: help 161 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Phenylalanine (F) to Cysteine (C) at position 161 (F161C, p.Phe161Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and aromatic (F) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In LRS. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.

Sequence information Variant position: help 161 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 2602 The length of the canonical sequence.
Location on the sequence: help PKQRLLGWIQNKIPYLPITN F NQNWQDGKALGALVDSCAPG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.


Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
Chain 1 – 2602 Filamin-B
Domain 139 – 242 Calponin-homology (CH) 2
Region 1 – 239 Actin-binding
Alternative sequence 1 – 169 Missing. In isoform 7.

Literature citations
Mutations in the gene encoding filamin B disrupt vertebral segmentation, joint formation and skeletogenesis.
Krakow D.; Robertson S.P.; King L.M.; Morgan T.; Sebald E.T.; Bertolotto C.; Wachsmann-Hogiu S.; Acuna D.; Shapiro S.S.; Takafuta T.; Aftimos S.; Kim C.A.; Firth H.; Steiner C.E.; Cormier-Daire V.; Superti-Furga A.; Bonafe L.; Graham J.M. Jr.; Grix A.; Bacino C.A.; Allanson J.; Bialer M.G.; Lachman R.S.; Rimoin D.L.; Cohn D.H.;
Nat. Genet. 36:405-410(2004)
Cited for: INVOLVEMENT IN SCT; VARIANTS LRS CYS-161; LYS-227; ASN-1571 DEL; ARG-1586 AND SER-1691; VARIANTS AO1 VAL-173 AND PRO-188; VARIANT AO3 ARG-751; VARIANT AO1/AO3 VAL-202; A molecular and clinical study of Larsen syndrome caused by mutations in FLNB.
Bicknell L.S.; Farrington-Rock C.; Shafeghati Y.; Rump P.; Alanay Y.; Alembik Y.; Al-Madani N.; Firth H.; Karimi-Nejad M.H.; Kim C.A.; Leask K.; Maisenbacher M.; Moran E.; Pappas J.G.; Prontera P.; de Ravel T.; Fryns J.-P.; Sweeney E.; Fryer A.; Unger S.; Wilson L.C.; Lachman R.S.; Rimoin D.L.; Cohn D.H.; Krakow D.; Robertson S.P.;
J. Med. Genet. 44:89-98(2007)
Cited for: VARIANTS LRS CYS-161; SER-168; LYS-227; VAL-234; SER-361; GLU-363; ARG-1431; ASN-1571 DEL; ARG-1586; ASP-1592; LEU-1603; SER-1691 AND ARG-1834;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.